Search results
This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the surveillance, diagnosis, and treatment of hepatocellular carcinoma (HCC) occur-ring in the setting of adults with cirrhosis.
This guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diag-nosed with hepatocellular carcinoma (HCC). A guid-ance document is different from a guideline.
5 mar 2021 · Download Full Issue. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. A. Vogel 1 ∙ E. Martinelli 2 on behalf of the ESMO Guidelines Committee. Download PDF.
31 sty 2019 · Hepatocellular carcinoma: ESMO Clinical Practice † Guidelines for diagnosis, treatment and follow-up. *Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org. †Approved by the ESMO Guidelines Committee: August 2018.
Early diagnosis and treatment of hepatocellular carcinoma are important because only 10% of patients meet the criteria for curative therapy at the time of diagnosis. Sev - eral organizations have developed guidelines for screening, diagnosis, and treatment of hepato - cellular carcinoma.
hepatocellular carcinoma. Key content includes diagnostic criteria, staging of disease, treatment plans and follow-up. The ESMO CPGs are intended to provide you with a set of recommendations for the best standards of care, using evidence-based medicine.
Early diagnosis of hepa-tocellular carcinoma remains a key goal in improving the poor prognosis of this form of liver cancer. Identify-ing hepatocellular carcinoma at an early stage is often associated with having better treatment options for pa-tients with small, asymptomatic tumors.
